Have you been diagnosed with heart failure due to decreased blood flow in the arteries i.e. coronary artery disease?
We are carrying out a clinical trial with an investigational drug that is being developed with the intention of treating patients with heart failure of ischemic origin (heart failure characterised by a reduced blood supply to the heart). The main purpose of the study will be to assess how safe the study drug is and to determine how long the study drug will remain in the body. We may also study how the study drug will affect the body. The information gathered during this clinical trial may be used to support further drug development, including larger trials in patients with heart failure.
This study will be conducted at our clinical trials unit in London Bridge – and will involve male and female patients with heart failure. You will need to attend a screening appointment to check if you are suitable to take part in the study. If you are suitable to take part we will invite you to the trial where you will attend our unit for two inpatient visits and outpatient visits as follows:
- First in-house period of 5 days / 4 nights. You will receive one dose of the study drug.
- Out-patient visit: Following the first in-house period, you will be required to attend the unit for an outpatient visit.
- Second in-house period of 5 days / 4 nights. You will receive one dose of the study drug, 27 days after receiving the first dose of the study drug.
- Three out-patient visits: Following the second in-house period, you will be required to attend the unit for three outpatient visits.
Screening and admission for the trial will be discussed during your telephone screening.
To be eligible for this trial you need to be:
- Male or female volunteers, aged between 30 and 80 (inclusive)
- You must be diagnosed with stable heart failure of ischaemic origin.
- You must have a Body Mass Index (BMI) within the range 18.0-28.0 kg/m² (inclusive).
You must have a body weight of less than or equal to 100 kg.
- You must not test positive for hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse (Alcohol abuse is defined as a regular weekly intake of more than 14 units).
- You must not have donated or lost blood within 16 weeks prior to first dosing.
- You must not be pregnant or breastfeeding.
- Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting one complete menstrual cycle prior to the first day of dosing and continuing until the follow-up visit.
- Male volunteers must be willing to use appropriate contraception for the duration of the study and for at least 3 months after the end of study visit. Female spouses or partners of the male volunteer must be willing to use appropriate contraception starting at least one complete menstrual cycle prior to the first day of dosing and continuing until at least 3 months after the end of study visit.
- You must agree not to donate sperm or ova (eggs) 3 months after end of study visit.
- Patients for this study are likely to be on medications including diuretics. Read here for a full overview.
A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.
Hear from one of our patients who recently participated in the study
In recognition of the time and effort involved in taking part in this study, you will receive £1,692 (£1,027 study payment, £505 bonus and up to £160 for travel expenses) on completion of the study provided you comply fully with all the study requirements. This amount is based on the anticipated study plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.Register your interest in this clinical trial
Contact our Volunteer Recruitment team
Or Email: firstname.lastname@example.org
Call us: weekdays between 09h00 and 17h00 on +44 (0) 207 042 5800 to speak to a member of our Volunteer Recruitment team.
Address: Richmond Pharmacology Ltd, 1A Newcomen Street, London Bridge, London, SE1 1YR
Ref: C18036_Apr 2019 (email_website_advert text)
This advertisement has been approved by an ethics committee and any response to this advert will be recorded but you will not be under any obligation to participate in the trial.
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.